drughunter.com
3 minute read
Sep. 2, 2019

A Non-Nitrogen Containing Morpholine Isostere

drughunter.com
Drug Hunter Team
Loading...
Join Drug Hunter to access scientifically rich molecule case studies, patent highlights, and structure search to spark research ideas in minutes. Get in touch by filling out the form below and a Drug Team member will be in touch with you and your team shortly.
Loading...

twitterlinkedinemail

Other articles you may be interested in

June 2024 News Roundup: FDA Approvals, Major Deals, Obesity Research Advances, and More

In June, we saw several FDA approvals for treatments targeting primary biliary cholangitis and COPD. The industry witnessed multibillion- and multimillion-dollar deals across various therapeutic areas. Advances were made in obesity therapeutics, with novel targets and clinical readouts for GLP-1 agonists and NLRP3 inhibitors. Alkermes and Takeda reported results for OX2R agonists in narcolepsy, while an antimalarial drug showed promise in PCOS. Despite these advancements, there were clinical trial failures for key molecules. Here's a recap of the most notable news highlights from June 2024!

SOS1 and SMARCA2 Degraders, RORγ and IRAK4 Inhibitors, and More: January 2024 Compound Collection

The team reviews hundreds of compounds from thousands of papers, press releases, and other sources each month to select candidates for Molecules of the Month. Here we have compiled a table of >70 additional molecules that were of interest in January 2024 along with highlights from some of our favorites, including molecules targeting SOS1, NLRP3, SMARCA2, and more.

June 2024 Molecule Roundup

To choose Molecules of the Month for June, our team reviewed hundreds of molecules from thousands of papers, press releases, conference presentations, and other sources. In this article, you'll find a curated selection of over 60 additional molecules from June that piqued our interest, along with highlights of some of our favorites and explanations of why they're worth keeping an eye on.

Six Deals and Funding Rounds from July You May Have Missed

In case you missed anything while you were away on summer holiday, here’s a recap of six notable deals from July to get you up to speed.

Patent Highlights: Nurr1 and Nur77 Modulators, STAT3 Inhibitors/Degraders, CDK2 Molecular Glue Degraders, ERAP1 Modulators, and More!

This article highlights key patents published in September 2024, covering a range of therapeutic targets and mechanisms. It includes Nurr1 and Nur77 modulators for oncology applications, STAT3 inhibitors and CRBN-based STAT3 degraders for modulating STAT3 signaling in cancer, and CDK2 molecular glue degraders for estrogen receptor-positive breast cancer resistant to CDK4/CDK6 inhibitors. Additionally, it features ERAP1 modulators for addressing autoimmune diseases, APOL1 inhibitors for APOL1-mediated kidney diseases, and novel NEK7 inhibitors targeting the NLRP3 inflammasome pathway.